Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2018 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Provides Operational Update

TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
December 05, 2017 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
November 30, 2017 10:45 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical

TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) and (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in...
October 13, 2017 17:45 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Closing of US$4 Million Financing

TORONTO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
October 11, 2017 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces US$4 Million Registered Direct Offering

TORONTO, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
October 10, 2017 17:20 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Third Quarter 2017 Results

TORONTO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
September 25, 2017 07:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA

TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
September 20, 2017 17:10 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Receipt of Nasdaq Notice

TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
September 05, 2017 14:35 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Provides Operational Update

TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
September 01, 2017 08:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Appoints New Chief Financial Officer

TORONTO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...